Krystal Biotech (NASDAQ:KRYS) Reaches New 52-Week High – Time to Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $382.54 and last traded at $371.67, with a volume of 309001 shares trading hands. The stock had previously closed at $378.15.

Wall Street Analysts Forecast Growth

KRYS has been the subject of several recent research reports. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, June 16th. TD Cowen increased their price objective on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, HC Wainwright boosted their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus target price of $340.56.

Krystal Biotech Stock Performance

The stock has a market capitalization of $10.96 billion, a price-to-earnings ratio of 49.69 and a beta of 0.53. The company has a fifty day simple moving average of $308.95 and a two-hundred day simple moving average of $278.93.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.66 earnings per share for the current year.

Insider Activity

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 in the last ninety days. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KRYS. Sound Income Strategies LLC lifted its stake in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the last quarter. Western Wealth Management LLC bought a new position in shares of Krystal Biotech in the 1st quarter valued at $34,000. Greenline Wealth Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter valued at $34,000. Danske Bank A S acquired a new position in shares of Krystal Biotech during the 3rd quarter worth $35,000. Finally, UMB Bank n.a. raised its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.